Potentiating intra-arterial sonothrombolysis for acute ischemic stroke by the addition of the ultrasound contrast agents (Optison™ and SonoVue®)
Transcranial ultrasound in combination with intravenously administered ultrasound contrast agents (UCA) in the presence or absence of recombinant tissue plasminogen activator (rt-PA) has been widely evaluated as a new modality for treatment of ischemic stroke. Despite the successful demonstration of...
| Main Authors: | , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
Springer Verlag
2010
|
| _version_ | 1826295655754104832 |
|---|---|
| author | Soltani, A Singhal, R Obtera, M Roy, RA Clark, WM Hansmann, DR |
| author_facet | Soltani, A Singhal, R Obtera, M Roy, RA Clark, WM Hansmann, DR |
| author_sort | Soltani, A |
| collection | OXFORD |
| description | Transcranial ultrasound in combination with intravenously administered ultrasound contrast agents (UCA) in the presence or absence of recombinant tissue plasminogen activator (rt-PA) has been widely evaluated as a new modality for treatment of ischemic stroke. Despite the successful demonstration of accelerated clot lysis there are inherent limitations associated with this modality such as inconsistency in temporal window thickness and/or potential serious cardiopulmonary reactions to intravenous administration of UCA that prevent broad application to ischemic stroke populations. As a complementary modality, we evaluated potential lysis enhancement by intra-arterial ultrasound with concurrent intra-clot delivery of UCA and rt-PA. To this end, clots were formed with average pore diameter similar to clinically retracted clots by adjusting the thrombin concentration. Physical characteristic and retention of UCA after delivery through the catheter as a function of clinically relevant flow rates of 6, 12, 18 ml/h were determined using a microscopic method. The ability of the UCA employed in this study, Optison and SonoVue, to penetrate into the clot was verified using ultrasound B-mode imaging. Clot lysis as a function of rt-PA concentration, 0.009 through 0.5 mg/ml, in the presence and absence of UCA diluted to 1:10, 1:100, and 1:200 v/v at two Peak rarefaction acoustic pressures of 1.3 and 2.1 MPa were evaluated using a weighing method. The study results suggest the addition of only 0.02 ml of 1:100 diluted UCA to rt-PA of 0.009, 0.05, 0.3, and 0.5 mg/ml can enhance the lysis rate by 3.9, 2.6, 1.9 and 1.8 fold in the presence of peak rarefaction acoustic pressure of 1.3 MPa and by 5.1, 3.4, 2.6, 3.1 in the presence of peak rarefaction acoustic pressure of 2.1 MPa, respectively. In addition, Optison and SonoVue demonstrated comparable effectiveness in enhancing the clot lysis rate. Addition of UCA to intra-arterial sonothrombolysis could be considered as a viable treatment option for ischemic stroke patients. |
| first_indexed | 2024-03-07T04:04:24Z |
| format | Journal article |
| id | oxford-uuid:c5a6e8d4-88df-4072-9c6b-d05d141cfcec |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T04:04:24Z |
| publishDate | 2010 |
| publisher | Springer Verlag |
| record_format | dspace |
| spelling | oxford-uuid:c5a6e8d4-88df-4072-9c6b-d05d141cfcec2022-03-27T06:32:38ZPotentiating intra-arterial sonothrombolysis for acute ischemic stroke by the addition of the ultrasound contrast agents (Optison™ and SonoVue®)Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:c5a6e8d4-88df-4072-9c6b-d05d141cfcecEnglishSymplectic Elements at OxfordSpringer Verlag2010Soltani, ASinghal, RObtera, MRoy, RAClark, WMHansmann, DRTranscranial ultrasound in combination with intravenously administered ultrasound contrast agents (UCA) in the presence or absence of recombinant tissue plasminogen activator (rt-PA) has been widely evaluated as a new modality for treatment of ischemic stroke. Despite the successful demonstration of accelerated clot lysis there are inherent limitations associated with this modality such as inconsistency in temporal window thickness and/or potential serious cardiopulmonary reactions to intravenous administration of UCA that prevent broad application to ischemic stroke populations. As a complementary modality, we evaluated potential lysis enhancement by intra-arterial ultrasound with concurrent intra-clot delivery of UCA and rt-PA. To this end, clots were formed with average pore diameter similar to clinically retracted clots by adjusting the thrombin concentration. Physical characteristic and retention of UCA after delivery through the catheter as a function of clinically relevant flow rates of 6, 12, 18 ml/h were determined using a microscopic method. The ability of the UCA employed in this study, Optison and SonoVue, to penetrate into the clot was verified using ultrasound B-mode imaging. Clot lysis as a function of rt-PA concentration, 0.009 through 0.5 mg/ml, in the presence and absence of UCA diluted to 1:10, 1:100, and 1:200 v/v at two Peak rarefaction acoustic pressures of 1.3 and 2.1 MPa were evaluated using a weighing method. The study results suggest the addition of only 0.02 ml of 1:100 diluted UCA to rt-PA of 0.009, 0.05, 0.3, and 0.5 mg/ml can enhance the lysis rate by 3.9, 2.6, 1.9 and 1.8 fold in the presence of peak rarefaction acoustic pressure of 1.3 MPa and by 5.1, 3.4, 2.6, 3.1 in the presence of peak rarefaction acoustic pressure of 2.1 MPa, respectively. In addition, Optison and SonoVue demonstrated comparable effectiveness in enhancing the clot lysis rate. Addition of UCA to intra-arterial sonothrombolysis could be considered as a viable treatment option for ischemic stroke patients. |
| spellingShingle | Soltani, A Singhal, R Obtera, M Roy, RA Clark, WM Hansmann, DR Potentiating intra-arterial sonothrombolysis for acute ischemic stroke by the addition of the ultrasound contrast agents (Optison™ and SonoVue®) |
| title | Potentiating intra-arterial sonothrombolysis for acute ischemic stroke by the addition of the ultrasound contrast agents (Optison™ and SonoVue®) |
| title_full | Potentiating intra-arterial sonothrombolysis for acute ischemic stroke by the addition of the ultrasound contrast agents (Optison™ and SonoVue®) |
| title_fullStr | Potentiating intra-arterial sonothrombolysis for acute ischemic stroke by the addition of the ultrasound contrast agents (Optison™ and SonoVue®) |
| title_full_unstemmed | Potentiating intra-arterial sonothrombolysis for acute ischemic stroke by the addition of the ultrasound contrast agents (Optison™ and SonoVue®) |
| title_short | Potentiating intra-arterial sonothrombolysis for acute ischemic stroke by the addition of the ultrasound contrast agents (Optison™ and SonoVue®) |
| title_sort | potentiating intra arterial sonothrombolysis for acute ischemic stroke by the addition of the ultrasound contrast agents optison™ and sonovue r |
| work_keys_str_mv | AT soltania potentiatingintraarterialsonothrombolysisforacuteischemicstrokebytheadditionoftheultrasoundcontrastagentsoptisonandsonovue AT singhalr potentiatingintraarterialsonothrombolysisforacuteischemicstrokebytheadditionoftheultrasoundcontrastagentsoptisonandsonovue AT obteram potentiatingintraarterialsonothrombolysisforacuteischemicstrokebytheadditionoftheultrasoundcontrastagentsoptisonandsonovue AT royra potentiatingintraarterialsonothrombolysisforacuteischemicstrokebytheadditionoftheultrasoundcontrastagentsoptisonandsonovue AT clarkwm potentiatingintraarterialsonothrombolysisforacuteischemicstrokebytheadditionoftheultrasoundcontrastagentsoptisonandsonovue AT hansmanndr potentiatingintraarterialsonothrombolysisforacuteischemicstrokebytheadditionoftheultrasoundcontrastagentsoptisonandsonovue |